Theseus Pharmaceuticals (THRX) Short Interest Ratio & Short Volume

Short interest is the volume of Theseus Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of January 31st, investors have sold 401,700 shares of THRX short. 2.63% of Theseus Pharmaceuticals' shares are currently sold short. Learn More on Theseus Pharmaceuticals' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.63% of Theseus Pharmaceuticals' floating shares are currently sold short.

Theseus Pharmaceuticals saw a decline in short interest in January. As of January 31st, there was short interest totaling 401,700 shares, a decline of 23.8% from the previous total of 527,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Theseus Pharmaceuticals currently has issued a total of 44,230,000 shares. Some of Theseus Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Theseus Pharmaceuticals currently has a public float of 15,300,000 shares.

2.63% of Theseus Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Theseus Pharmaceuticals: NGM Biopharmaceuticals, Inc. (4.52%), Kinnate Biopharma Inc. (2.01%), Omeros Co. (23.62%), 908 Devices Inc. (5.16%), Kodiak Sciences Inc. (3.76%), INmune Bio, Inc. (12.66%), Alpha Tau Medical Ltd. (0.08%), Candel Therapeutics, Inc. (12.96%), Skye Bioscience, Inc. (0.29%), The Joint Corp. (5.34%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($4.48 billion), General Motors ($3.85 billion), Charter Communications, Inc. ($3.38 billion), Occidental Petroleum Co. ($3.00 billion), Super Micro Computer, Inc. ($2.66 billion), Tractor Supply ($2.37 billion), Coinbase Global, Inc. ($2.25 billion), Moderna, Inc. ($2.11 billion), Royal Caribbean Cruises Ltd. ($2.06 billion), and Floor & Decor Holdings, Inc. ($1.67 billion). View all of the most shorted stocks.

Short selling THRX is an investing strategy that aims to generate trading profit from Theseus Pharmaceuticals as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Theseus Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of THRX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including THRX, twice per month. The most recent reporting period available is January, 31 2024.